Skip To Main Content
Teh-Ying Chou on Muck Rack

Teh-Ying Chou

As seen in: ScienceDirect, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Teh-Ying

Contact Teh-Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

|
By Elise J. Needham, Jørgen F.P. Wojtaszewski, Teh-Ying Chou, Wendy Cooper
| ScienceDirect Verified
Over the last decade, checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)1 and its ligand programmed death-ligand 1 (PD-L1) have revolutionized clinical practice in many indications, including melanoma, non-small cell lung cancer, breast cancer, renal cell carcinoma, urothelial carcinoma (UC), hepatocellular carcinoma, and more.
Open in Who Shared Issue with article?
See all 1 articles